GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Marvel Biosciences Corp (OTCPK:MBCOF) » Definitions » Return-on-Tangible-Asset

MBCOF (Marvel Biosciences) Return-on-Tangible-Asset : -850.31% (As of Jan. 2025)


View and export this data going back to 2023. Start your Free Trial

What is Marvel Biosciences Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Marvel Biosciences's annualized Net Income for the quarter that ended in Jan. 2025 was $-1.35 Mil. Marvel Biosciences's average total tangible assets for the quarter that ended in Jan. 2025 was $0.16 Mil. Therefore, Marvel Biosciences's annualized Return-on-Tangible-Asset for the quarter that ended in Jan. 2025 was -850.31%.

The historical rank and industry rank for Marvel Biosciences's Return-on-Tangible-Asset or its related term are showing as below:

MBCOF' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -416.37   Med: -283.75   Max: -151.03
Current: -416.37

During the past 5 years, Marvel Biosciences's highest Return-on-Tangible-Asset was -151.03%. The lowest was -416.37%. And the median was -283.75%.

MBCOF's Return-on-Tangible-Asset is ranked worse than
96.06% of 1499 companies
in the Biotechnology industry
Industry Median: -36.2 vs MBCOF: -416.37

Marvel Biosciences Return-on-Tangible-Asset Historical Data

The historical data trend for Marvel Biosciences's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Marvel Biosciences Return-on-Tangible-Asset Chart

Marvel Biosciences Annual Data
Trend Jul20 Jul21 Jul22 Jul23 Jul24
Return-on-Tangible-Asset
-323.29 -221.56 -147.48 -285.20 -277.51

Marvel Biosciences Quarterly Data
Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -164.34 -229.59 -564.71 -308.40 -850.31

Competitive Comparison of Marvel Biosciences's Return-on-Tangible-Asset

For the Biotechnology subindustry, Marvel Biosciences's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Marvel Biosciences's Return-on-Tangible-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Marvel Biosciences's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Marvel Biosciences's Return-on-Tangible-Asset falls into.


;
;

Marvel Biosciences Return-on-Tangible-Asset Calculation

Marvel Biosciences's annualized Return-on-Tangible-Asset for the fiscal year that ended in Jul. 2024 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Jul. 2024 )  (A: Jul. 2023 )(A: Jul. 2024 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Jul. 2024 )  (A: Jul. 2023 )(A: Jul. 2024 )
=-1.203/( (0.509+0.358)/ 2 )
=-1.203/0.4335
=-277.51 %

Marvel Biosciences's annualized Return-on-Tangible-Asset for the quarter that ended in Jan. 2025 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Jan. 2025 )  (Q: Oct. 2024 )(Q: Jan. 2025 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Jan. 2025 )  (Q: Oct. 2024 )(Q: Jan. 2025 )
=-1.352/( (0.166+0.152)/ 2 )
=-1.352/0.159
=-850.31 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Jan. 2025) net income data.


Marvel Biosciences  (OTCPK:MBCOF) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Marvel Biosciences Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Marvel Biosciences's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Marvel Biosciences Business Description

Traded in Other Exchanges
Address
505 - 8th Avenue SW, Suite 420, Calgary, AB, CAN, T2P1G2
Marvel Biosciences Corp is a life sciences company focused on the discovery and development of a synthetic derivative compound of a known drug. It has developed several new chemical entities, using synthetic chemical derivatives of known, off-patent drugs, that inhibit the A2a adenosine receptor with application to neurological diseases (depression & anxiety, Alzheimer's, ADHD), and the non-neurological conditions of cancer and non-alcoholic steatohepatitis. Marvel is also exploring additional undisclosed targets to expand its asset pipeline.